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The success of antigen-specific immunotherapies for 
allergy (Canonica et al., 2014) reinforces the notion that 
tolerogenic vaccination will be a therapeutic option for 
autoimmune diseases in a foreseeable future. However, and 
despite promising preclinical studies, results from clinical trials 
have been so far disappointing, and autoimmune diseases 
are still treated with nonspecific immunosuppressors. The 
difficulty in translating preclinical data may well relate to 
their lack of robustness, an issue that is amenable. Daniel et 
al. reported complete prevention of type 1 diabetes (T1D) in 
serum insulin autoantibody low (IAAlow) nonobese diabetic 
(NOD) mice treated with R22E (a.k.a. mimetope-3; B12 :23 
-R22E), whether treatment was initiated at 4 or 12 wk of 
age. This spectacular outcome has prompted human studies 
testing this peptide (e.g., Nakayama et al., 2015). We sought 
to explore the mechanisms behind the preventive effect of 
R22E in NOD mice and specifically test the requirement for 
continuous thymic output for de novo tolerance induction 
in this system (Zelenay et al., 2010; Paiva et al., 2013), which 
lead us to probe its robustness.
We analyzed two independent NOD colonies, #1 and 
#2, derived from breeders imported 18 yr ago or during 
the course of this study, and presenting 53.2% and 83.3% 
T1D incidence in females, respectively (Fig. S1, A and B). In 
both colonies, IAA titers measured at 4 wk of age were low 
(4w-IAAlow) and provided no prediction power (Fig. S1, C, D, 
and G). In 6-wk-old mice (Fig. S1, E–H), titers spread over 3 
logs, linear regression analysis established the optimal thresh-
old for T1D predictability at 0.1, and selection for 6w-IAAlow 
titers (<0.1) delayed disease onset and reduced T1D inci-
dence. These results are concordant with earlier experiments 
reporting that IAA titers are low at 4, and predictive of disease 
at 8, wk of age (Zhang et al., 2008). Daniel et al. (2011) state 
that 95% of the mice were 4w-IAAlow, although the repre-
sentative data identify 25% of the mice as 4w-IAAhigh. Titer 
distribution in 12-wk-old animals is not indicated. Moreover, 
control animals, presumably selected as IAAlow (at 4 and 12 
wk of age, in the respective figures), display high incidence 
and usual onset of disease, suggesting the measurements had 
little predictive power.
To test whether R22E treatment is protective in our 
NOD colonies, we followed the protocol described in Daniel 
et al. (2011). Females IAAlow (<0.1) received highly purified 
R22E for 14 d, through a subcutaneous osmotic pump de-
livering 5 µg/day. We chose this dose as it is shown to confer 
100% protection in each of the several experiments presented 
in Daniel et al. (2011), and doses twofold lower or two- to 
fourfold higher are reported to also afford protection. We 
followed the manufacturer’s recommendation to remove the 
osmotic pump after the 2-wk treatment, both to ensure preci-
sion in the dose and regimen of peptide delivery and to avoid 
“swelling and leaking of a concentrated salt solution, result-
ing in local irritation around the pump” (Alzet mini-pump 
instructions). To ascertain that surgical intervention was not 
a confounding factor, control mice in colony #2 were sham 
operated. Moreover, mice from colonies #1 and #2 received 
peptide from independent batches, the latter from the same 
supplier as Daniel et al. (2011). Surprisingly, mice selected 
as 4w-IAAlow and immediately treated showed no reduction 
in hyperglycemia, irrespectively of whether they belonged to 
colony #1 (P = 0.9777) or #2 (P = 0.3365; Fig. 1, A and B). 
As we monitored a total of 21 treated mice, and Daniel et al. 
(2011) showed 100% protection in a group of 12 animals, a 
putative discrepancy in IAAlow preselection does not explain 
differences in the qualitative assessment of disease protection. 
We next monitored mice that were classified as IAAlow at 6 
wk of age and were treated, or not, with R22E in the follow-
ing days. We choose this age with confidence because Dan-
Daniel et al. (https ://doi .org /10 .1084 /jem .20110574) have previously published in JEM a study on the preventive effect of 
tolerogenic vaccination with a strong agonist insulin mimetope in type 1 diabetes. Our study now challenges these results and 
shows that osmotic pump delivery of the modified insulin peptide R22E did not prevent hyperglycemia, accelerated disease 
onset, increased its incidence, and worsened insulitis.
Tolerogenic insulin peptide therapy precipitates type 1 
diabetes
Marie-Louise Bergman,1 Thiago Lopes-Carvalho,1 Ana-Catarina Martins,1 Fabio A. Grieco,2 
Décio L. Eizirik,2 and Jocelyne Demengeot1
1Instituto Gulbenkian de Ciência, Oeiras, Portugal
2Center for Diabetes Research, Université Libre de Bruxelles, Brussels, Belgium
© 2017 Bergman et al. This article is distributed under the terms of an Attribution–Noncommercial–Share 
Alike–No Mirror Sites license for the first six months after the publication date (see http ://www .rupress .org 
/terms /). After six months it is available under a Creative Commons License (Attribution–Noncommercial–
Share Alike 4.0 International license, as described at https ://creativecommons .org /licenses /by -nc -sa /4 .0 /).
Correspondence to Jocelyne Demengeot: jocelyne@igc.gulbenkian.pt
Abbreviations used: IAA, insulin autoantibody; NOD, nonobese diabetic; SFB, seg-
mented filamentous bacteria; T1D, type 1 diabetes.
 o
n
 D
ecem
ber 7, 2017
jem.rupress.org
D
ow
nloaded from
 
http://doi.org/10.1084/jem.20160471
Supplemental material can be found at: 
Peptide therapy precipitates autoimmunity | Bergman et al.2154
iel et al. (2011) reported total prevention of disease when 
treating 12-wk-old animals. Mice were either maintained 
euthymic (Fig. 1 C), sham operated (Fig. 1 D), or thymec-
tomized (Fig. 1 E) before treatment. Of note, sham surgery 
per se lowered the incidence of T1D, whereas effective thy-
mus removal reverted this effect, emphasizing that our NOD 
colony is responsive to small effects promoting disease pro-
tection. Intriguingly, disease onset was precipitated, and T1D 
incidence was systematically higher in R22E-treated than in 
untreated mice (no surgery: 72.7% vs. 40.9%, P = 0.024; sh-
am-thymectomy: 60% vs. 15.4%, P = 0.0221; thymectomy: 
85.7% vs. 38.5%, P = 0.0017). The observed increased T1D 
incidence and earlier disease onset in animals treated at 7 but 
not at 4 wk of age is best explained by the high efficiency of 
IAA based selection in the former group of mice, with low 
and late T1D incidence allowing for worsening to be revealed.
The finding that R22E treatment is not protective in 
our NOD cohorts while it fully prevents disease in Daniel 
et al. (2011) evokes previous discordant studies. Similar treat-
ment with the native insulin peptide B9:23 prevented dis-
ease in 50% (Liu et al., 2002) or none (Daniel et al., 2011) 
of the NOD mice analyzed. In our setting, osmotic pump 
delivery of B9:23 in 6w-IAAlow females increased disease in-
cidence when compared with control mice (75% vs. 40.9%, 
P = 0.0345; Fig. 1 F). The mice tested by Daniel et al. (2011) 
were imported from the Taconic facility, where segmented fil-
amentous bacteria (SFB), reported to reduce T1D incidence 
in NOD females (Kriegel et al., 2011), is present. Specific 
16S-PCR on fecal extract (Vaishnava et al., 2011) detected 
SFB in ≥80% of our experimental mice (colony #1) and in 
all breeders (colony #2) <3 mo after importation (not de-
picted), excluding this bacterium as a confounding factor.
 Finally, we assessed whether R22E treatment affected 
insulitis severity. Blinded examination of pancreatic sections 
from 30-wk-old normoglycemic mice revealed lower fre-
quency of insulin-producing islets and higher frequency of 
severely infiltrated islets in treated compared with control 
animals (Fig.  2), indicating that R22E also worsens clini-
cally silent insulitis.
By addressing the efficacy of R22E in NOD mice and 
several possible confounding physiological factors such as age, 
putative genetic drift, thymic output, or experimental fac-
tors such as peptide synthesis and purification, we found the 
protection reported previously not to be reproducible. Upon 
sharing these findings with C. Daniel, we could not ascertain 
repeats have been successful elsewhere or with other colonies 
(e.g., NOD-Foxp3GFP treated but not scored for disease in 
Daniel et al. [2011]) and came across a procedural discrepancy. 
Figure 1. R22E treatment anticipates disease onset and increases T1D incidence. NOD females selected for serum IAA titers <0.1 were treated with 
the indicated peptides (filled symbols) for 14 d (filled area), and glycemia was monitored weekly from 10 to 30 wk of age. (A and B) Screen and osmotic 
pump insertion were performed at 4 wk of age in females from colonies #1 (A) and #2 (B). Control mice from colony #2 (B) underwent sham surgeries 
(Ctrl-Sham). (C–E) Females from colony #1, IAAlow at 6 wk of age, were implanted 1 wk later with osmotic pumps containing R22E (C) or were first submitted 
to sham-thymectomy (SHAM-TX; D) or full thymectomy (TX; E). (F) As in C, except B9 :23 -containing osmotic pumps. Treated mice are from two (A, C, and 
F), four (B), and three (D and E) independent experiments with n = 1 and 11 in A; n = 3, 5, 6, and 6 in B; n = 9 and 12 in C; n = 5, 1, and 4 in D; n = 7, 2, and 
5 in E; and n = 5 and 7 in F. Log-rank tests statistical differences for T1D incidence in Kaplan-Meier survival plots: not significant in A (P = 0.977) and B (P 
= 0.3365); significant in C (P = 0.0240), D (P = 0.0221), E (P = 0.0017), and F (P = 0.0345). Controls are different animals between panel C and F, and from 
those presented in Fig. S1.  o
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Despite the specification that the treatment duration was of 
14 d, and elsewhere in the text from 4 to 6 wk of age, the 
authors left the pump in place for the full length of the ex-
periments, i.e., 40 wk. As referred above, the mishandling of 
osmotic pump can induce inflammation, and inflammation 
per se has been shown multiple times to lower T1D inci-
dence, delay its onset, or even confer full protection in NOD 
mice. It is also expected that the pump would release another 
22 µl of peptide solution after the 14 d, corresponding to an 
extension of the treatment for an estimated 3.5 d. Hence, it 
remains possible that pump-induced inflammation in combi-
nation or not with extended R22E administration generated 
a false-positive treatment outcome in Daniel et al. (2011).
Our work suggests that failure in translating preclinical 
studies may relate to their lack of robustness and, in turn, 
supports the notion that the NOD mouse remains a suitable 
model for screening candidate therapies for human T1D. As 
confounding factors in procedures are best revealed through 
independent repeats and because variability across inbred col-
onies pales compared with the heterogeneity of humans par-
ticipating in clinical trials, we stress that translation must only 
be considered when peptide, or any other, therapy is robust 
across centers and animal facilities. This is particularly acute 
when results, such as ours, reveal cases of disease worsening.
MaTERials anD METhODs
Mice
NOD/Lt breeders for colony #1 and #2 were purchased 
from The Jackson Laboratory in 1998 and 2014, respectively, 
and maintained at the Instituto Gulbenkian de Ciência (IGC) 
animal facility under specific pathogen–free conditions, ac-
cording to the Federation for Laboratory Animal Science As-
sociation guidelines. Mice were sacrificed at 30 wk of age 
or when confirmed diabetic. Experimental protocols were 
approved by the Portuguese authority (Direção Geral de Ali-
mentação e Veterinária) and the ethical committee of the IGC.
Diabetes monitoring
Blood glucose levels were monitored weekly from 10 wk of 
age with ACCU-CHEK AVI VA Glucose strips (Roche). Mice 
were considered diabetic after two consecutive measurements 
>200 mg/dl and one positive test of urine glycosuria (Diabur 
Test 5000 glucose strips, #10647659074; Roche).
iaa detection
Serum IAA levels were measured by Time-Resolved 
Fluorescence DEL FIA immunoassay on a Victor3 Multilabel 
Counter fluorimeter (Wallac). ELI SA Plates (#206072; 
Santa Cruz Biotechnology, Inc.) were coated with human 
recombinant insulin (100 U/ml, Humulin Regular; Lilly), 
blocked with 2% BSA (#A9647; Sigma Aldrich) and 
incubated sequentially with sera (1/10), biotinylated anti–
mouse IgG1 Ab (1/5,000, #ab11587; Abcam), Europium-
labeled Streptavidin (1/2,000, #1244-360; PerkinElmer) and 
DEL FIA Enhancement solution (#1244, PerkinElmer). Each 
sera was measured in two independent assays. On each plate, 
a standard curve was generated from serial dilution of a pool 
of IAAhigh sera, and the first dilution was given a value 10. 
The best-fit trend line of the standard curve was determined 
using Excel. The equation of the trend line, the R2 value, 
and the concentration of each sample were generated 
using www .Elisaanalysis .com.
Figure 2. R22E treatment worsens insulitis in normoglycemic mice. Pancreas sections from nine control and six R22E-treated females normo-
glycemic at 30 wk of age (see Fig. 1 C) were scored blindly, all together at once, for insulitis severity. (A and B) Representative stainings used to identify 
insulin-producing islets (insulin/glucagon/Hoechst; A) and to score islets infiltration (hematoxylin and eosin; B). Bars, 100 µm. (C) Frequency of insu-
lin-producing islets. (D) Frequency of infiltrated islets along a severity score (4 is most severe). ND, <50 islets detected.
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histology and immunofluorescence
Pancreatic tissue from NOD mice was paraffin embedded, sec-
tioned, and hematoxylin and eosin–stained. Islets were scored 
blindly for immune infiltration as follows: 0, no infiltration; 1, 
periinsulitis; 2, infiltration in <50% of the area; 3, >50% of the 
area; and 4, islets completely destroyed. Insulin and glucagon 
were stained with primary monoclonal mouse anti-insulin 
Ab (1/1000; SIG MA) and polyclonal rabbit anti-glucagon Ab 
(1/100; Dako) and secondary Abs Alexa Fluor 488 goat anti–
mouse IgG (H+L) and Alexa Fluor 546 goat anti–rabbit IgG 
(H+L) (1/500; Molecular Probes, Invitrogen), respectively. 
After Hoechst 33342 nuclear staining, immunofluorescence 
was visualized on an Axio ImagerA1 microscope (ZEI SS).
Peptides and osmotic pumps
R22E and B9:23 from Thermo Fisher Scientific (>95% pu-
rity) were used to treat colony #1 and R22E from New 
England Peptide (>90% purity) to treat colony #2. Peptides 
were administered subcutaneously at a rate of 0.25 µl/h, cor-
responding to 5 µg/day, over 14 d, through micro-osmotic 
pumps (Alzet model 1002, Charles River), inserted and ex-
planted by aseptic surgery. Where indicated, control mice were 
sham operated, both at the insertion and the removal times.
Thymectomy and sham-thymectomy
Thymectomies were performed in aseptic conditions on 
6-wk-old mice under ketamine/xylazine anesthesia. Sh-
am-thymectomy was surgery without removal of thymic lobes.
statistical analysis
T1D incidence was determined using Kaplan-Meier sur-
vival plots, statistically significant differences (P < 0.05) with 
Log-rank tests, and linear regression analysis were used to 
calculate the proportion of T1D onset explained by IAA 
titers. Statistical analysis was performed with Prism soft-
ware (GraphPad Software).
Online supplemental material
Fig. S1 shows an age-dependent correlation between IAA 
titer and T1D onset in two NOD colonies.
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